Effects of estrogen on functional and neurological recovery after spinal cord injury: An experimental study with rats

Letaif, Olavo Biraghi; Cristante, Alexandre Fogaça; Filho, Tarcísio Eloy Pessoa de Barros; Ferreira, Roberta Machado; Santos, Gustavo Bispo dos; Rocha, Ivan Dias da; Marcon, Raphael Martus

doi:10.6061/clinics/2015(10)08

Cited by 21 publications

(26 citation statements)

References 19 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rats also underwent MEP recordings of the amplitude and latency of the responses in the paws on both sides following transcranial electrical stimulation 13 . MEP was performed under anesthesia on the 42 nd day after spinal cord lesioning, the day of euthanasia.…”

Section: Methodsmentioning

confidence: 99%

“…This study was motivated by the possibility of the synergetic use of G(M1) and erythropoietin as an adjuvant treatment of spinal lesions based on a consistent line of evidence from studies of experimental lesions in rats 10 - 15 . The use of these two substances together indicates a possible breakthrough in the quality of neural regeneration, stemming from the principle that minimal anatomical repairs of the spinal cord can result in clinically significant improvements in patients who experience spinal cord lesions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations

Marcon

Cristante

Filho

et al. 2016

Clinics

Self Cite

View full text Add to dashboard Cite

OBJECTIVE:To evaluate the functional and histological effects of ganglioside G(M1) and erythropoietin after experimental spinal cord contusion injury.METHODS:Fifty male Wistar rats underwent experimental spinal cord lesioning using an NYU-Impactor device and were randomly divided into the following groups, which received treatment intraperitoneally. The G(M1) group received ganglioside G(M1) (30 mg/kg); the erythropoietin group received erythropoietin (1000 IU/kg); the combined group received both drugs; and the saline group received saline (0.9%) as a control. A fifth group was the laminectomy group, in which the animals were subjected to laminectomy alone, without spinal lesioning or treatment. The animals were evaluated according to the Basso, Beattie and Bresnahan (BBB) scale, motor evoked potential recordings and, after euthanasia, histological analysis of spinal cord tissue.RESULTS:The erythropoietin group had higher BBB scores than the G(M1) group. The combined group had the highest BBB scores, and the saline group had the lowest BBB scores. No significant difference in latency was observed between the three groups that underwent spinal cord lesioning and intervention. However, the combined group showed a significantly higher signal amplitude than the other treatment groups or the saline group (p<0.01). Histological tissue analysis showed no significant difference between the groups. Axonal index was significantly enhanced in the combined group than any other intervention (p<0.01).CONCLUSION:G(M1) and erythropoietin exert therapeutic effects on axonal regeneration and electrophysiological and motor functions in rats subjected to experimental spinal cord lesioning and administering these two substances in combination potentiates their effects.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations

Marcon

Cristante

Filho

et al. 2016

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“… 38 When comparing male rats in the control group with those in the E2 treatment group following SCI, the E2-treated group showed significant improvement in transmission of neural impulses while the control group displayed a significant decrease in the number of neurons in the histologic findings. 56 …”

Section: Neuroprotective Mechanisms Of E2 In Animal Modelsmentioning

confidence: 99%

Neuroprotective effects of estrogen in CNS injuries: insights from animal models

Raghava¹,

Das²,

Ray³

2017

NAN

View full text Add to dashboard Cite

Among the estrogens that are biosynthesized in the human body, 17β-estradiol (estradiol or E2) is the most common and the best estrogen for neuroprotection in animal models of the central nervous system (CNS) injuries such as spinal cord injury (SCI), traumatic brain injury (TBI), and ischemic brain injury (IBI). These CNS injuries are not only serious health problems, but also enormous economic burden on the patients, their families, and the society at large. Studies from animal models of these CNS injuries provide insights into the multiple neuroprotective mechanisms of E2 and also suggest the possibility of translating the therapeutic efficacy of E2 in the treatment SCI, TBI, and IBI in humans in the near future. The pathophysiology of these injuries includes loss of motor function in the limbs, arms and their extremities, cognitive deficit, and many other serious consequences including life-threatening paralysis, infection, and even death. The potential application of E2 therapy to treat the CNS injuries may become a trend as the results are showing significant therapeutic benefits of E2 for neuroprotection when administered into the animal models of SCI, TBI, and IBI. This article describes the plausible mechanisms how E2 works with or without the involvement of estrogen receptors and provides an overview of the known neuroprotective effects of E2 in these three CNS injuries in different animal models. Because activation of estrogen receptors has profound implications in maintaining and also affecting normal physiology, there are notable impediments in translating E2 therapy to the clinics for neuroprotection in CNS injuries in humans. While E2 may not yet be the sole molecule for the treatment of CNS injuries due to the controversies surrounding it, the neuroprotective effects of its metabolite and derivative or combination of E2 with another therapeutic agent are showing significant impacts in animal models that can potentially shape the new treatment strategies for these CNS injuries in humans.

show abstract

“…O número de animais (n) necessários para a formação dos grupos foi baseado na padronização da MASCIS e em estudos anteriores que adotaram modelo experimental semelhante. 17,27,108 O sistema NYU Impactor possui três graduações de altura da haste (12,5 mm, 25 mm e 50 mm). Em nosso estudo, optamos pela altura da haste de 12,5 mm por acreditarmos que a queda de uma altura de 25 mm provoca mais alterações anatomopatológicas que alterações funcionais e a queda de altura de 50 mm apresenta taxas de lesão medular completa e mortalidade elevadas.…”

Section: Discussionunclassified

“…14,17 A eritropoetina tem papel hormonal estabelecido na manutenção da homeostase das hemácias circulantes e também atua reduzindo o estresse metabólico em muitos tecidos, como produtor molecular. 18 Alguns estudos demonstraram efeito protetor da eritropoetina na lesão medular isquêmica em coelhos 19 e na lesão traumática em ratos 3 e coelhos.…”

unclassified

Avaliação do efeito da interleucina-6 e da eritropoetina na lesão medular em ratos

Barros¹

View full text Add to dashboard Cite

DEDICATÓRIAAos meus pais, José Roberto e Márcia, pelo suporte e amor incondicional, apesar da distância e dos obstáculos.Às minhas irmãs Carolina, Gabriella e Daniella, por sempre me incentivarem a buscar meus objetivos e a relação de amor que mantemos, mesmo distante, há tantos anos. AGRADECIMENTOSAo Professor Doutor Alexandre Fogaça Cristante, pela oportunidade e incentivo ao desenvolvimento acadêmico e aprimoramento de conhecimentos.Ao Professores Doutores, Tarcísio Eloy de Barros Filho, Olavo Pires de Camargo e Gilberto Camanho, por permitirem o acesso a esta casa, referência em ensino e pesquisa para o profissional que deseja ingressar na carreira acadêmica e docência.Aos meus mentores e referências em cirurgia de coluna:Dr. Luís Eduardo Carelli Teixeira da Silva, pelo brilhantismo e paixão que transmite no dia a dia da prática médica; Dr. Luís Claúdio Vilella Schettino, pelo estímulo, exemplo de ética e pelas portas abertas em minha vida profissional; Dr. André Luíz Loyelo Barcellos, pela dedicação e incentivo ao meu desenvolvimento como médico especialista em coluna vertebral e compromisso com os pacientes; À Dra. América Maria Mendonça Limoeiro, pelo carinho e proteção materna recebidos durante todos esses anos no Rio de Janeiro; Ao amigo Rodrigo José Fernandes da Costa, pela parceira e ajuda gratuita ao longo dos anos, amigo fiel de todos os momentos; Ao biólogo Gustavo Bispo dos Santos, pela dedicação e profissionalismo. publicam artigo de revisão sobre as implicações terapêuticas da IL-6 e reforçam sua importância na contribuição para as defesas do hospedeiro contra infecções. Entretanto, sua síntese exagerada num ambiente de estresse pode levar a uma resposta sistêmica grave, fenômeno conhecido como "cytokine storm". NORMATIZAÇÃO ADOTADANessa revisão, os autores propõem que a possibilidade de bloqueio da IL-6 pode constituir uma nova estratégia terapêutica para uma resposta sistêmica patológica. EritropoetinaEm 1906, Paul Carnot, um professor de medicina na França, e sua assistente, Clotilde Deflandre, propõem a teoria de que a produção de glóbulos vermelhos do sangue é regulada por hormônios. 57Após a realização de experimentos em coelhos sujeitos a sangria, os pesquisadores atribuem o aumento das células vermelhas do sangue desses coelhos a um fator humoral chamado hemopoietina. Formação dos grupos experimentaisOs 50 animais foram divididos em cinco grupos:-Grupo EPO: Após lesão medular, os animais receberam eritropoietina recombinante (EPO), na dose de 100 UI/100 g, fabricada pela indústria farmacêutica Janssen-Cilag (Eprex-alfaepoetina, Schaffhausen, Suíça) em ampolas com doses de 10.000 UI e volume de 1 ml, administrada por via intraperitoneal diariamente durante três semanas. 114-Grupo EPO + IL-6: Eritropoetina + Interleucina-6 (IL 6). Após lesão medular:EPO na mesma dose e IL-6 na dose de 200 UI/100 g, Actemra, nome genérico tocilizumabe (caixas com 1 frasco-ampola contendo 4 mL de tocilizumabe), fabricada pelo Laboratório Roche, administrada por via intraperitoneal diariamente, também durant...

show abstract

Effects of estrogen on functional and neurological recovery after spinal cord injury: An experimental study with rats

Cited by 21 publications

References 19 publications

Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations

Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations

Neuroprotective effects of estrogen in CNS injuries: insights from animal models

Avaliação do efeito da interleucina-6 e da eritropoetina na lesão medular em ratos

Contact Info

Product

Resources

About